News Eikon prices its IPO, seeking to raise $318m Roger Perlmutter's new cancer biotech Eikon has priced its IPO, looking to raise up to $318m and achieve a $900m-plus valuation.
News AgomAb and SpyGlass push the IPO button Glimmers of a renewal of biotech IPO activity in 2026 have continued with the news that AgomAb and SpyGlass Pharma are sizing up investor interest.
News Perlmutter's Eikon follows the IPO trail Two more biotechs have joined the Nasdaq IPO queue, namely Roger Perlmutter's cancer biotech Eikon and hair loss drug developer Veradermics.
News RNA specialist Ribo files $205m IPO in Hong Kong Chinese RNA-based medicine developer Ribo has filed a Hong Kong IPO to raise cash for its siRNA drug for thrombotic diseases.
News Aktis Oncology files much-expanded IPO Aktis Oncology has filed its IPO, seeking to raise up to around $210 million in what could be the first biotech listing on the Nasdaq in 2026.
News Insilico ends 2025 with $293m Hong Kong IPO One of the pioneers in AI-powered drug discovery, Insilico Medicine, has completed an oversubscribed IPO in Hong Kong, raising around $293m.
Patients LSX2026: On promise and patience, with Hans Schambye At LSX World Congress 2026 in Lisbon, Portugal, web editor Nicole Raleigh spoke with Hans Schambye, CEO of BOOST Pharma.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
